Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease

Authors

  • Joseph O'Neill PhD,

    1. Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    2. Department of Radiology and Neurology, University of California, San Francisco, California USA
    Search for more papers by this author
  • Norbert Schuff PhD,

    1. Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    2. Department of Radiology and Neurology, University of California, San Francisco, California USA
    Search for more papers by this author
  • William J. Marks Jr. MD,

    1. Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    2. Department of Neurology, University of California, San Francisco, California, USA
    Search for more papers by this author
  • Robert Feiwell MD,

    1. Department of Radiology and Neurology, University of California, San Francisco, California USA
    Search for more papers by this author
  • Michael J. Aminoff MD,

    1. Center for Parkinson's Disease and Movement Disorders, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    2. Department of Neurology, University of California, San Francisco, California, USA
    Search for more papers by this author
  • Michael W. Weiner MD

    Corresponding author
    1. Magnetic Resonance Unit, Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    2. Department of Radiology and Neurology, University of California, San Francisco, California USA
    • MR Unit, DVAMC 114M, 4150 Clement Street, San Francisco, CA 9412
    Search for more papers by this author

Abstract

Magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopy (MRS) of the substantia nigra, basal ganglia, and cerebral cortex were performed on 10 patients with Parkinson's disease (PD) and 13 age-matched, healthy control subjects. Compared to controls, PD patients had approximately 24% lower creatine in the region of the substantia nigra and smaller volumes of the putamen (11%), globus pallidus (16%), and prefrontal cortex (6%; all P < 0.05). No other significant between-group differences were found in nine regions examined. Thus, quantitative MRI may show regional neurodegenerative changes outside the substantia nigra in PD but PD-linked extranigral metabolic abnormalities, if they exist, may be difficult to detect with current 1H MRS methods. In additional, exploratory tests, volumes of the caudate (r = −0.56), putamen (r = −0.66), and globus pallidus (r = −0.60; all P < 0.05) were negatively correlated with the volume of the substantia nigra pars compacta in controls. In PD these correlations did not hold. Instead, pallidal volume in PD was positively correlated with compacta volume (r = 0.64; P < 0.05). This relationship suggests that basal ganglia volumes may be influenced by dopaminergic innervation from the substantia nigra in normal and PD subjects. © 2002 Movement Disorder Society

Ancillary